Epitomics spins off mAb company Apexigen

Burlingame, CA-based Epitomics has spun off a new biotech called Apexigen, which will focus on developing humanized monoclonal antibodies for treatment of cancer and immuno-disorders. Apexigen was formed with exclusive rights to develop and commercialize therapeutic monoclonal antibodies derived from Epitomics' rabbit monoclonal antibody technology and the mutational lineage guided humanization technology. The company will use the technologies to develop therapies for both...